Hepatectomy Followed by Adjuvant Chemotherapy With Capecitabine Plus Oxaliplatin for Colorectal Cancer Liver Metastases
In this single-arm, phase II study, the authors evaluated the use of 3 months of adjuvant capecitabine plus oxaliplatin (CAPOX) following curative-intent resection of colorectal liver metastases in 28 patients. The 5-year recurrence-free and overall survival rates were 65% and 87%, respectively. The use of 3 months of adjuvant CAPOX following surgery may be an effective strategy for patients with colorectal liver metastases.